Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.54 |
| ▸ | GRPR | P30550 | 2/20 | 0.54 |
| ▸ | GLP1R | P43220 | 7/20 | 0.53 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.51 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | EDNRA | P25101 | 1/20 | 0.49 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30690366 | 0.98 | GRPR (0.55) | RXFP1GRPRGLP1RPCSK9NPBWR1 | |
| SCHEMBL30690371 | 0.95 | PCSK9 (0.54) | RXFP1GRPRGLP1RPCSK9NPBWR1 | |
| SCHEMBL30690374 | 0.94 | GLP1R (0.54) | RXFP1GRPRGLP1RPCSK9NPBWR1 | |
| SCHEMBL30690361 | 0.94 | GLP1R (0.54) | RXFP1GRPRGLP1RPCSK9NPBWR1 | |
| SCHEMBL29443915 | 0.88 | GLP1R (0.64) | RXFP1GLP1RMAGI3ECE1MUS81 | |
| SCHEMBL30690354 | 0.86 | RXFP1 (0.63) | RXFP1GRPRGLP1RECE1MUS81 | |
| SCHEMBL29742991 | 0.86 | EDNRA (0.54) | RXFP1GRPRGLP1RPCSK9NPBWR1 | |
| SCHEMBL31536185 | 0.85 | PRMT1 (0.55) | GRPRPCSK9NPBWR1PRMT1EDNRA | |
| SCHEMBL30690379 | 0.84 | OPRD1 (0.60) | GLP1RNPBWR1ECE1MUS81 | |
| SCHEMBL29359110 | 0.84 | RXFP1 (0.59) | RXFP1GRPRGLP1RPCSK9EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806365-B2 | Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis | CELGENE CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION | 2022-10-13 | — | — | US | disclosed |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CELGENE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220106404-A1 | CHIMERIC ANTIGEN RECEPTORS | CELGENE CORPORATION | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CD79B, BCL6, CD22 | RXFP1 4557/4885GRPR 3226/4885GLP1R 4654/4885 |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CD79B, BCL6, CD22 | RXFP1 4557/4885GRPR 3226/4885GLP1R 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.